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Latin America (LA), defined here as the countries in the West-
ern hemisphere located south of the United States, is a region
with a total population of nearly 520,000,000 that increases 1.5%
annually and has a human development index of 0.77. The coun-
tries that form this region present extreme contrasts. These con-
trasts are first and foremost within the countries themselves,
because extremes of wealth and poverty are present in their
social and economic fabric. In addition, in LA a vast variety of
government modalities and political systems are represented.
Therefore, in order for prevention strategies to be effective,
they need to be tailored to the specific characteristics and id-
iosyncrasies of individual nations. This article will address the
following aspects: first, a broad outline of the basic health statis-
tics in LA, with focus on treatment of end-stage renal disease
and its derived economic burden. Data from LA countries will
be contrasted with 95% confidence interval of corresponding
data from 10 industrialized countries (Canada, France, Ger-
many, Italy, Japan, United Kingdom, United States, Spain, Swe-
den, and Switzerland). Second, we will discuss the prevalence
of some risk factors for end-stage renal disease in the nations of
the region. For this reason, we will focus on data that provide
reliable information. Finally, we will consider general guidelines
for the implementation of prevention strategies that may have
common applicability in LA countries.
WEALTH AND HEALTH IN LATIN AMERICA
Latin American (LA) countries have a mean gross do-
mestic product (GDP)/capita of US $3.55, but the range
extends from $12.79 (Argentina) to $2.40 (Cuba). Even
the upper level is well below the 95% confidence interval
(CI) of the chosen sample of industrialized countries (US
$23.63-$29.17) [1]. The lack of uniformity in LA countries
is manifested in the wide range of different wealth and
health indicators. The proportion of individuals that live
under the poverty line, represented by an income of less
than US $1 per day, ranges from 55% (Guatemala) to
5% to 15% (Colombia, Venezuela, Mexico, and Chile)
[2]. The proportion of the population without access to
potable water ranges from 55% (Paraguay) to less than
5% (Uruguay) [3], and the proportion of the population
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without adequate sanitation ranges from 42% (Ecuador)
to 5% to 6% (Chile, Costa Rica, Cuba, and Uruguay) [4].
Life expectancy at birth in LA is 70.5 years, but it ranges
from 50 to 76.9 years, and expectation of a healthy life at
birth ranges from 42.9 to 66.6 years. Life expectancy is
correlated with gross national product (Fig. 1) [5].
LA countries have a mean of 153.4 physicians and 139
nurses per 100,000 inhabitants, but the range extends
from 8.4 (Haiti) to 530 (Cuba) in the case of doctors,
and from 10.7 to 677 in the case of nurses. The deficit is
particularly evident in nurses, who are outnumbered by
doctors 1.5 to 7 times in the majority of LA countries
[6]. With the exception of Cuba and Jamaica, the sum of
doctors and nurses is in deficit, with respect to the num-
ber in industrialized countries (Fig. 2). Therefore, it may
be assumed that a shortage of doctors and nurses will
dictate that their participation in prevention strategies
will be limited. In specific countries and, particularly, in
specific regions within a country with an overwhelming
deficit of health personnel, planning of prevention strate-
gies should probably include task-oriented training and,
of course, adequate supervision of selected individuals in
the community.
Relative expenditure in health in most LA countries is
lower than in industrialized countries (Fig. 3A), ranging
from 10.9% of the GDP in Uruguay to 2.4% in Ecuador
[1]. More importantly, the actual expenditure in health
in LA countries (mean = US $391 per capita per year;
range, 78 to 1061) is 8 to 10 times lower than the cor-
responding figure in the developed world (Fig. 3B). It is
obvious that the burden of optimal health care (for our
purposes, defined as health care provided in the chosen
sample of developed countries) cannot be met by LA na-
tions, and deep inequalities in coverage and delivery are
an inescapable reality that may only be mitigated with
a concerted effort that includes reduction in the cost of
essential drugs.
END-STAGE RENAL DISEASE IN LA
The Sociedad Latinoamericana de Nefrologı´a e
Hipertensio´n (SLANH) keeps a registry of end-stage re-
nal disease (ESRD) and its treatment modalities in 20
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Fig. 1. Life expectancy is correlated with GDP per capita. Shaded
square denotes the mean and 95% confidence interval of these values
in the sample of industrialized countries chosen for comparison (see
text).
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Fig. 2. Mumber of medical doctors and nurses in LA compared with
the corresponding number in industrialized countries. Dotted lines in-
dicate the 95% confidence interval in industrialized countries; only 1
country (Jamaica) is within those limits. The rest of the countries are
well below these limits, and 1 country (Cuba) has more health personnel
than in the sample of industrialized countries.
nations of LA. The Dialysis Registry collects data from
14 of 20 countries and the Transplant Registry from 18
of 20 countries, and those data correspond with roughly
90% and 96% of the population in LA, respectively. Ac-
cording to the SLANH registry [7, 8], there has been a
steady increase in all modalities of treatment from 192
patients per million (ppm) in 1992 to 349 ppm in 2001.
The projection is that in 2005, there will be about 450
ppm (Fig. 4). In chronic dialysis, the registry from 2001
included a total of 277.1 ppm, of which 197 ppm were on
hemodialysis and 80.1 ppm on peritoneal dialysis. There
are countries with a relatively high prevalence of patients
under treatment (>600 ppm: Puerto Rico and Uruguay),
whereas the rest of the countries have an intermediate
(300–600 ppm: Chile, Argentina, and Mexico), low (100–
300 pmm: Brazil, Colombia, Cuba, Ecuador, Guatemala,
Peru, and Venezuela), or very low prevalence (<100 ppm:
Costa Rica and Paraguay). The SLANH has estimated
that there is an unmet demand of 40 ppm and, conse-
quently, 19 patients with ESRD do not receive treatment
[7, 8]. As it is elsewhere in the world, in LA there has
been a steady increase in the proportion of patients with
diabetes and uncontrolled hypertension with ESRD; in
LA, these etiologies represent at present 33% and 32%,
respectively, of patients on chronic dialysis (Fig. 5).
It is evident that care of renal patients imposes increas-
ing economic, human, and technical demands that have
a greater impact in countries with lower GDP and health
systems already overburdened with unsatisfied needs of
primary care for the general population. As shown in
Table 2, in the majority of countries, costs of chronic dial-
ysis are largely covered by public funds (social security
system and health budget), and participation of the pri-
vate sector (health insurance companies) is very limited.
The mean cost of hemodialysis in the 11 LA countries is
US $11.55 ± 4.96 per patient per year, but it ranges from
US $7.33 in Brazil to US $23.00 in Costa Rica. Dialyzer
reuse has become an important cost-reducing strategy;
countries in which dialyzer reuse is practiced in more than
90% of patients have 2 to 3 times lower costs than those
in which reuse is not a common practice (Table 2). Never-
theless, care of the patient with ESRD cannot be covered
adequately with budget allocations, and therefore, repre-
sents one of the more obvious examples of inequality of
access and delivery of medical care in LA.
Nearly 60,000 patients have received renal transplan-
tation in LA. In the last 2 to 3 years, the number of
transplants in the region has remained steady at 5.4 to
5.6 renal transplants per year, roughly 55% of which are
from living related donors, except in Argentina, Chile,
Cuba, Uruguay, and Venezuela, where the proportion of
cadaveric donors is 60% or higher [7, 8].
SOME RISK FACTORS IN LA
Hypertension
The prevalence of hypertension (systolic blood pres-
sure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg)
in some LA countries has been reviewed in a consen-
sus conference [9]. The mean value of the prevalence
of hypertension in LA is 27.8% (22% in Peru to 33%
in Uruguay). However, as shown in Table 1, more than
half of the patients with hypertension ignore that they
have high blood pressure, 30% of these patients are ac-
tually treated (18.2% in Paraguay to 42% in Argentina
and Uruguay), and only 18.7% are considered to be con-
trolled (6.7% in Ecuador to 22% in Mexico). Because
one third of ESRD is reported to be the result of un-
controlled hypertension in LA (Fig. 5), blood pressure
evaluation and control are likely to have a major impact
in the prevalence of ESRD in the region.
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Fig. 3. The national expenditure in health is shown as a percentage of the GDP (A) and in US dollars per capita (B). Dotted lines represent the
95% confidence interval in industrialized countries.
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Fig. 4. Yearly increment of patients in all modalities of treatment for
ESRD. In 2005, it is projected that LA will have 450 patients pmp on
renal replacement therapies.
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Fig. 5. Etiology of patients on chronic dialysis in LA. Hyperten-
sion (32%) and diabetic nephropathy (33%) make up two thirds of
patients.
Low birth weight
Evidence is accumulating in favor of the postulate that
low birth weight (<2500 g) may play a role in adult hy-
pertension and chronic renal disease inasmuch as there is
a correlation between reduced birth weight and nephron
number [10]. Although in industrialized countries only
5.6% of newborns have low birth weight, in LA the pro-
portion is 10% (Fig. 6), ranging from 5% in Chile and
Paraguay to 15% in Haiti and Nicaragua [11]. Strate-
gies to improve pregnancy control and maternal nutrition
will likely have an impact in reducing this potential risk
factor.
Table 1. Hypertension in selected Latin American countries
Prevalence% Known% Treated% Controlled%
Argentina 28.1 54 42 14.3
Brazil 26.8 50 30 10
Chile 22–8 43 26.1 8.2
Cubaa 30 75 NA NA
Ecuador 28.7 41 23 6.7
Mexicob 30.5 28 38 22
Paraguay 30.5 33.5 18.3 7.8
Peru 22 40 20 10
Uruguay 33 68 42 11
Venezuela 32–4 47 37 8.5
NA, not available. Values taken from Consenso Latinoamericano sobre hipe-
tensio´n arterial. J Hypertens (Edicio´n en Espan˜ol) 6:1–27, 2001.
aDE LA OSA JA: Hipertensio´n arterial. Available at://consulta.cuba.cu;
SALAZAR J, AGUILAR J: Prevalencia de la hipertensio´n arterial en un con-
sultorio me´dico de familia. Available at: www.bvs.sld.cu/revistas/san/vol2 4 98/
san02498.htm
bVELAZQUEZ-MONROY O, ROSAS PERALTA M, LARA ESQUEDA A, et al:
Prevalence and interrelations of non-communicable chronic diseases and cardio-
vascular risk factors in Mexico. Final outcomes from the National Health Survey
2000. Arch Cardiol Mex 73:62–77, 2003
Diabetes
Diabetes is an increasingly important risk factor in
ESRD. It has been estimated that 19 million patients with
diabetes exist in LA, and projections are that the number
of patients with diabetes in 2025 will reach 64 million [12].
The direct cost of diabetes has been calculated to be US
$703 per capita per year. If we assume that similar costs
are applicable in LA countries, the value would repre-
sent twice the mean health expenditure per capita in the
region (Fig. 7) [13].
OUTLINE OF STRATEGIES FOR PREVENTION
OF ESRD IN LA
Prevention strategies need to involve government au-
thorities, the medical community, and the general public.
Only with the participation of all these separate com-
partments is there a reasonable chance of success in any
prevention strategy. The cooperation of health admin-
istration, health personnel, and public opinion is best
assured enlisting the effort of local societies of nephrol-
ogy. The leadership of national societies of nephrology is
pivotal to the implementation of any prevention strategy
because in these societies there are generally medical and
academic resources with open lines of communication
to administrative government levels. In addition, medi-
cal societies have the capacity to reach out to the gen-
eral public to increase awareness and develop currents of
opinion. The International Society of Nephrology (ISN),
through the Commission for the Global Advancement
of Nephrology (COMGAN), has already established a
working relationship with almost every one of the na-
tional societies of nephrology in LA, as well as with
SLANH. The following strategies are recommended:
ISN-COMGAN has been supporting conferences and
symposia dedicated to prevention that are organized by
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Table 2. Costs of hemodialysis in Latin American countries
Source of coverage%
Cost/session Cost patient/ Dialyzer reuse
Country US $ year US $ % patients Gov SS Private
Argentina 65 9360 100 7 86 7
Bolivia 80 9600 100
Brazil 47 7332 95 95 5
Colombia 90 14,040 0 40 60
Costa Rica 150 23,000 0 100
Chile 54 8510 95 95 5
Ecuador 60 9000 100
Mexico 89 12,876 0 95
Peru 44 6864 90 99 1
Uruguay 57 8892 95 100a
Venezuela 112 17,550 0 10 90b
Mean ± SD 77 ± 32 11,547 ± 4962
Abbreviations are: Gov, health budget of the government; SS, social security. Costs include supplies and services. Costs were obtained by personal communication
with nephrologists in individual countries.
aNational resource fund.
bSocial security funds include government and workers.
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Fig. 6. Low birth weight in LA. The mean in-
cidence of live births of less than 2500 g is 2
times higher than that in industrialized coun-
tries.
nephrologic societies in each individual country. In these
activities, there is joint participation of ISN-COMGAN
speakers and local specialists. As a rule, these meetings
are widely praised and have a strong local participa-
tion. These activities need to be continued and streng-
thened.
The prevalence of some risk factors for ESRD, for in-
stance proteinuria and microalbuminuria, are unknown
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in LA is contrasted with calculated direct costs
estimated to be caused by diabetes.
or only partially known, in most regions of LA. Epidemi-
ologic studies in representative populations need to be
encouraged and supported. Help may be required in the
design and evaluation of epidemiologic studies, because
only 48% of the studies to estimate the prevalence of hy-
pertension in LA published between 1966 and 2000 met
a critical threshold to be useful for surveillance purposes
[14].
The participation of national health authorities may be
encouraged by promoting high-level governmental pro-
grams, such as “The sustainable and tenable renal health
model: A Latin American proposal of classification, pro-
gramming and evaluation” designed by Rafael Burgos
and Santos Delpine [15]. This program aims to integrate
a renal health model into national public health policies,
and has already been approved in Chile and is presently
been applied in Valdivia.
Access of information to nephrology practitioners may
be accomplished through periodicals or by the Internet.
Full-text access to nephrology journals is important to
support academic nephrology. Although Internet users
still represent a relatively low percentage of the LA pop-
ulation, ranging from <1% (Cuba) to 20% (Chile), their
numbers have risen dramatically in all LA nations (with
the exception of Cuba) to 45 to 50 million users in 2005
[16]. More than 90% of the users are professionals, and
8 to 9 of every 10 individuals in academic positions have
Internet access in the most populated countries in LA
[17]. Academic nephrology is probably the core of most
potential prevention strategies. The strength of academic
nephrology in LA is limited by the lack of free access to
full-text articles, because budget limitations have reduced
and/or eliminated medical library subscriptions, and the
cost of 5 widely read nephrologic journals (American
Journal of Kidney Diseases, American Journal of Phys-
iology Renal Physiology, Journal of the American Society
of Nephrology, Kidney International, Nephrology Dialy-
sis Transplantation) is equivalent to 1 month (Brazil) to
4 months’ (Paraguay) salary of a full-time associate pro-
fessor in LA countries.
Last, but by no means least, is the cost of medication in
any prevention program. The vast majority of the popula-
tion in LA countries cannot afford the cost of medications
that are currently known to slow progression of renal fail-
ure. Therefore, the burden of purchasing and delivering
these medications to individuals at risk must be taken by
LA governments that need to be convinced of the eco-
nomic benefit of prevention strategies and offer the drugs
at an affordable cost.
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